{
    "code": "52026579",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026579",
    "time": "2023-04-14 03:41:35",
    "許可證字號": "衛部藥輸字第026579號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "114\/12\/11",
    "發證日期": "104\/12\/11",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202657909",
    "中文品名": "泰伏樂膠囊75毫克",
    "英文品名": "Tafinlar Capsules 75mg",
    "適應症": "1. 黑色素瘤: Dabrafenib 單一療法或與trametinib 併用，可用於治療BRAF V600 突變陽性且無法以手術切除或轉移性的成人黑色素瘤 ( 請參閱第5.1 節)。\r\n2. 黑色素瘤的輔助治療: Dabrafenib 與trametinib 併用，可用於治療BRAF V600 突變且完全切除後之第III 期黑色素瘤病人的術後輔助治療。\r\n3. 非小細胞肺癌: Dabrafenib 與trametinib 併用，可用於治療BRAF V600 突變之晚期非小細胞肺癌成人病人。",
    "劑型": "130膠囊劑",
    "包裝": "8-1000粒塑膠瓶裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "109\/12\/11",
    "主成分略述": "Dabrafenib Mesylate (Micronized)",
    "限制項目": "02輸　入 5F免除銜接性試驗",
    "申請商名稱": "0924601100  台灣諾華股份有限公司",
    "申請商地址": "臺北市中山區民生東路3段2號8樓",
    "主製造廠": [
        {
            "製造廠名稱": "FSI0003000  LEK PHARMACEUTICALS D.D",
            "製造廠廠址": "VEROVSKOVA 57, SL-1526 LJUBLJANA, SLOVENIA",
            "製造廠公司地址": "",
            "製造廠國別": "SLOVENIA",
            "製程": "成品製造、一級包裝、二級包裝"
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "6132061151  裕利股份有限公司",
            "製造廠廠址": "桃園市大園區和平里1鄰開和路91號",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "二級包裝廠(委託貼標及置入仿單)"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013005310",
            "成分名稱": "Dabrafenib Mesylate (Micronized)",
            "含量描述": "(eq. to Dabrafenib..….75 MG)",
            "含量": "88.8800000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "026579_Tafinlar Capsules 75mg-108-06-24(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026579&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "3_依核定草本印妥之仿單_Tafinlar Capsules -TWI-140122-111-01-22.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026579&Seq=012&Type=9"
        },
        {
            "title": "泰伏樂膠囊_75mg_中文標籤-TWL-200521-110-10-29(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026579&Seq=009&Type=8"
        },
        {
            "title": "泰伏樂膠囊_75mg_LBL-110-10-29(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026579&Seq=008&Type=8"
        },
        {
            "title": "泰伏樂膠囊_75mg_FB-110-10-29(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026579&Seq=007&Type=8"
        },
        {
            "title": "026579_Tafinlar Capsules 75mg-108-06-24(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026579&Seq=006&Type=8"
        },
        {
            "title": "020265790003-104-12-31.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026579&Seq=005&Type=8"
        }
    ]
}